Epigenetic markers of esophageal cancer: DNA methylation


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅存取

详细

Adenocarcinoma and squamous cell carcinoma are the most common types of esophageal malignant tumors. Their constant tendency to the increase in morbidity and high mortality rate underlie importance of the search for new biomarkers that complement and improve the early diagnosis of this disease. Despite significant efforts undertaken in this field the only marker of esophageal cancer, the ERBB2/HER2 status, is used in routine clinical practice. This review summarizes data on epigenetic markers characterizing aberrant methylation of the genome, which may be useful for early detection of esophageal cancer, prognosis and/or prediction of response to treatment. The development of new high-throughput technologies of genome-wide screening, such as BeadChip array and immunoprecipitation followed by sequencing, used not only for genome-wide genotyping, but also for the analysis of transcriptome and methylome, provides a comprehensive picture of genetic and epigenetic changes during tumorigenesis.

作者简介

O. Kit

Rostov Cancer Research Institute

Email: dvodolazhsky@gmail.com
俄罗斯联邦, ul. 14th Line 63, Rostov-on-Don, 344037

D. Vodolazhskiy

Rostov Cancer Research Institute

编辑信件的主要联系方式.
Email: dvodolazhsky@gmail.com
俄罗斯联邦, ul. 14th Line 63, Rostov-on-Don, 344037

E. Kolesnikov

Rostov Cancer Research Institute

Email: dvodolazhsky@gmail.com
俄罗斯联邦, ul. 14th Line 63, Rostov-on-Don, 344037

N. Timoshkina

Rostov Cancer Research Institute

Email: dvodolazhsky@gmail.com
俄罗斯联邦, ul. 14th Line 63, Rostov-on-Don, 344037

补充文件

附件文件
动作
1. JATS XML

版权所有 © Pleiades Publishing, Ltd., 2017